A CAPS-based binding assay provides semi-quantitative validation of protein-DNA interactions

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• Protein-DNA interactions are fundamental to gene regulation.
• Existing methods like DNaseI footprinting and gel shift assays are often costly, labor-intensive, and use hazardous labels.
• There is a need for simpler, safer, and more efficient techniques to study these interactions.

Purpose of the Study:

• To introduce and validate a novel, label-free assay for studying protein-DNA interactions.
• To provide a semi-quantitative method for assessing the strength of protein-DNA binding.
• To offer a cost-effective and less laborious alternative to current methods.

Main Methods:

• Development of a cleaved amplified polymorphic sequence (CAPS)-based binding assay (CBA).
• The assay relies on changes in restriction endonuclease site accessibility in amplified DNA upon protein binding.
• Demonstration using B3 and MADS3 proteins with RY or CArG-box containing DNA sequences.

Main Results:

• The CBA successfully detected and semi-quantitatively assessed protein-DNA interactions.
• The assay demonstrated a dose-dependent response based on the concentration of the binding protein.
• Validation was achieved using known protein-DNA pairs (B3/MADS3 proteins and their target DNAs).

Conclusions:

• The CAPS-based binding assay (CBA) is a feasible and effective label-free method for studying protein-DNA interactions.
• CBA simplifies the validation of these interactions, offering a semi-quantitative readout.
• This novel assay presents a valuable alternative for gene regulation studies, reducing cost and labor.